CN120360984A - 用于维持或调节人体组织中醚脂质分子混合物的组合物 - Google Patents
用于维持或调节人体组织中醚脂质分子混合物的组合物Info
- Publication number
- CN120360984A CN120360984A CN202510328121.7A CN202510328121A CN120360984A CN 120360984 A CN120360984 A CN 120360984A CN 202510328121 A CN202510328121 A CN 202510328121A CN 120360984 A CN120360984 A CN 120360984A
- Authority
- CN
- China
- Prior art keywords
- ether
- groups
- composition
- lipid
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Pediatric Medicine (AREA)
- Birds (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019902527 | 2019-07-17 | ||
| AU2019902527A AU2019902527A0 (en) | 2019-07-17 | Compositions and methods of use | |
| CN202080065491.1A CN114502149A (zh) | 2019-07-17 | 2020-07-17 | 用于维持或调节人体组织中醚脂质分子混合物的组合物 |
| PCT/AU2020/050742 WO2021007623A1 (en) | 2019-07-17 | 2020-07-17 | Compositions for maintaining or modulating mixtures of ether lipid molecules in a tissue of a human subject |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080065491.1A Division CN114502149A (zh) | 2019-07-17 | 2020-07-17 | 用于维持或调节人体组织中醚脂质分子混合物的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120360984A true CN120360984A (zh) | 2025-07-25 |
Family
ID=74209622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510328121.7A Pending CN120360984A (zh) | 2019-07-17 | 2020-07-17 | 用于维持或调节人体组织中醚脂质分子混合物的组合物 |
| CN202080065491.1A Pending CN114502149A (zh) | 2019-07-17 | 2020-07-17 | 用于维持或调节人体组织中醚脂质分子混合物的组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080065491.1A Pending CN114502149A (zh) | 2019-07-17 | 2020-07-17 | 用于维持或调节人体组织中醚脂质分子混合物的组合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220257616A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3999044A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7890196B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220047775A (cg-RX-API-DMAC7.html) |
| CN (2) | CN120360984A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022000814A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147249A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289859A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022000664A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021007623A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115236170B (zh) * | 2022-07-25 | 2024-11-26 | 清华大学 | 基于毛细管电泳的脂质组分析系统及其应用和脂质组的分析方法 |
| WO2024148052A1 (en) | 2023-01-03 | 2024-07-11 | Baker Heart and Diabetes Institute | Ether of phosphatidylcholine and phosphatidylethanolamine, their lyso-forms and mixture thereof for use in the treatment of treatment of a disease or disorder caused by a deficiency in plasmalogens |
| EP4661856A1 (en) * | 2023-02-10 | 2025-12-17 | Baker Heart and Diabetes Institute | Plasmalogen modulation of immune cells |
| WO2026008605A2 (en) | 2024-07-01 | 2026-01-08 | Pelagic Ai Limited | Chemical synthesis of bioactive precursors to plasmalogens |
| WO2026008716A1 (en) | 2024-07-02 | 2026-01-08 | Baker Heart and Diabetes Institute | Methods of use for plasmalogen precursors in treating plasmalogen-associated diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1029610A (en) | 1965-04-08 | 1966-05-18 | Shell Int Research | Improvements in or relating to ethers |
| US4046914A (en) | 1966-12-16 | 1977-09-06 | Astra Nutrition Ab | Therapeutically active substituted saturated and mono-and polyunsaturated alkyl-glycerylethers |
| JPS56133281A (en) | 1980-03-21 | 1981-10-19 | Kao Corp | Preparation of glyceryl ether |
| US4613621A (en) | 1981-09-18 | 1986-09-23 | Hoerrmann Wilhelm | Fatty aldehydes and acids in the treatment of neurological and inflammatory diseases |
| US4595681A (en) * | 1984-10-26 | 1986-06-17 | The United States Of America As Represented By The United States Department Of Energy | Antihypertensive neutral lipid |
| SE8800182L (sv) | 1988-01-21 | 1989-07-22 | Kaernerud Lars Haelsoprod | Anvaendning av alkylglycerol foer framstaellning av ett laekemedel |
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US6121245A (en) | 1997-01-29 | 2000-09-19 | Firshein; Richard N. | Method of treating cancer using alkylglycerols in conjunction with chemotherapy |
| SE9701912D0 (sv) | 1997-05-22 | 1997-05-22 | Interhealth Ab | Pharmaceutical composition and use thereof |
| US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
| US20070191495A1 (en) | 2004-01-16 | 2007-08-16 | Fuji Oil Company, Limited | Lipase inhibitor |
| FR2874156B1 (fr) | 2004-08-13 | 2007-04-06 | Univ Rennes 1 Etablissement Pu | Complement alimentaire pour animaux d'elevage et procede de mise en oeuvre de celui-ci |
| US20090131368A1 (en) | 2006-07-19 | 2009-05-21 | Su Chen | Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species |
| EP2064544A1 (en) | 2006-09-14 | 2009-06-03 | Zora Biosciences OY | Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk |
| WO2009050692A2 (en) * | 2007-10-16 | 2009-04-23 | Vascular Biogenics Ltd. | Platelet-activating factor (paf) analogs and uses thereof |
| US8975299B2 (en) | 2007-11-01 | 2015-03-10 | Enzymotec Ltd. | Lipid mixture for infant nutrition |
| EP2403491A2 (en) | 2009-03-04 | 2012-01-11 | Nestec S.A. | Alkylglycerols and alkoxyglycerols for increasing endogenous plasmalogen levels in mammals |
| FR2945951B1 (fr) | 2009-05-26 | 2012-07-13 | Polaris | Composition d'akg et son utilisation pour la fabrication d'un medicament. |
| DE102009022907A1 (de) * | 2009-05-27 | 2010-12-09 | Kdg Mediatech Ag | Optischer Datenträger |
| EP2309276A1 (en) | 2009-09-22 | 2011-04-13 | One Way Liver Genomics, S.L. | Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile |
| KR101787618B1 (ko) | 2010-09-24 | 2017-10-18 | 후지노 브레인 리서치 가부시키가이샤 | 항중추신경계 염증제 |
| JP5709304B2 (ja) | 2011-01-06 | 2015-04-30 | 日光ケミカルズ株式会社 | 水中油型乳化化粧料 |
| CA2812178C (en) | 2011-11-17 | 2014-11-04 | Phenomenome Discoveries Inc. | Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof |
| EP2810079A4 (en) * | 2012-01-31 | 2015-08-05 | Teknologian Tutkimuskeskus Vtt Oy | PROCESS FOR DETERMINING THE LIVERY QUANTITY OF LIQUID AND METHOD FOR DIAGNOSIS OF NAFLD |
| KR101639128B1 (ko) | 2013-10-29 | 2016-07-13 | 울산대학교 산학협력단 | 플라스마로젠 전구체, 플라스마로젠 또는 플라스마로젠 유사체를 유효성분으로 함유하는 간질환 예방 또는 치료용 약학조성물 |
| WO2015196250A1 (en) | 2014-06-27 | 2015-12-30 | Commonwealth Scientific And Industrial Research Organisation | Lipid comprising docosapentaenoic acid |
| WO2016041013A1 (en) | 2014-09-16 | 2016-03-24 | Baker Idi Heart And Diabetes Institute Holdings Limited | Glycerolipids and uses therefor |
| CN107080249A (zh) | 2016-06-30 | 2017-08-22 | 健糖(北京)健康管理有限公司 | 一种供糖尿病人群食用的配方食品及其制备工艺 |
-
2020
- 2020-07-17 BR BR112022000814A patent/BR112022000814A2/pt unknown
- 2020-07-17 KR KR1020227005189A patent/KR20220047775A/ko active Pending
- 2020-07-17 CN CN202510328121.7A patent/CN120360984A/zh active Pending
- 2020-07-17 CN CN202080065491.1A patent/CN114502149A/zh active Pending
- 2020-07-17 MX MX2022000664A patent/MX2022000664A/es unknown
- 2020-07-17 CA CA3147249A patent/CA3147249A1/en active Pending
- 2020-07-17 WO PCT/AU2020/050742 patent/WO2021007623A1/en not_active Ceased
- 2020-07-17 JP JP2022503457A patent/JP7890196B2/ja active Active
- 2020-07-17 EP EP20839957.6A patent/EP3999044A4/en active Pending
- 2020-07-17 US US17/597,659 patent/US20220257616A1/en active Pending
-
2022
- 2022-01-15 IL IL289859A patent/IL289859A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021007623A1 (en) | 2021-01-21 |
| EP3999044A1 (en) | 2022-05-25 |
| BR112022000814A2 (pt) | 2022-03-08 |
| AU2020314798A1 (en) | 2022-02-24 |
| JP7890196B2 (ja) | 2026-07-14 |
| IL289859A (en) | 2022-03-01 |
| KR20220047775A (ko) | 2022-04-19 |
| JP2022541277A (ja) | 2022-09-22 |
| EP3999044A4 (en) | 2023-10-18 |
| CN114502149A (zh) | 2022-05-13 |
| US20220257616A1 (en) | 2022-08-18 |
| CA3147249A1 (en) | 2021-01-21 |
| MX2022000664A (es) | 2022-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220257616A1 (en) | Compositions for maintaining or modulating mixtures of ether lipid molecules in a tissue of a human subject | |
| Meng et al. | Indole-3-lactic acid, a metabolite of tryptophan, secreted by Bifidobacterium longum subspecies infantis is anti-inflammatory in the immature intestine | |
| Kuda et al. | Docosahexaenoic acid–derived fatty acid esters of hydroxy fatty acids (FAHFAs) with anti-inflammatory properties | |
| JP5876114B2 (ja) | アミロイドベータ凝集抑制剤 | |
| JP5934483B2 (ja) | リン脂質結合型dha増加剤 | |
| Guo et al. | Different metabolism of EPA, DPA and DHA in humans: A double-blind cross-over study | |
| US20230330040A1 (en) | Immunological effects of metabolites | |
| Guerra et al. | Plasma phospholipidomic profile differs between children with phenylketonuria and healthy children | |
| JP2012036100A (ja) | 抗アレルギー剤 | |
| CN102413822A (zh) | 提高哺乳动物中内源性缩醛磷脂水平的方法 | |
| Bardanzellu et al. | Clinical insights gained through metabolomic analysis of human breast milk | |
| Ma et al. | Characterization of gangliosides in three sea urchin species by HILIC–ESI-MS/MS | |
| Grindel et al. | Cheek cell fatty acids reflect n-3 PUFA in blood fractions during linseed oil supplementation: a controlled human intervention study | |
| Böcking et al. | Bioavailability and allergoprotective capacity of milk-associated conjugated linoleic acid in a murine model of allergic airway inflammation | |
| JP2024059594A (ja) | プラズマローゲン含有組成物、プラズマローゲンの製造方法、プラズマローゲン合成促進用培地、抗炎症剤、抗炎症用経口組成物、認知機能改善剤、認知機能改善用経口組成物、神経細胞死抑制剤及び神経細胞死抑制用経口組成物 | |
| WO2012060718A1 (en) | Preventing or treating metabolic syndrome by administering a trans fatty acid, or a salt, ester or precursor thereof, or sialic acid in free or bound form | |
| JP2008266326A (ja) | 発芽玄米脂質画分を有効成分とする神経障害予防又は改善剤 | |
| Kussmann | Nutrition and immunity | |
| Wang et al. | Comparative analysis of human milk glycosphingolipids from different secretor mothers using HILIC-MS/MS | |
| WO2019244140A1 (ja) | 腎機能維持及び保護剤、並びに、その効果評価方法 | |
| AU2024219028A1 (en) | Plasmalogen modulation of immune cells | |
| Alshammari | Sickle cell disease associated lipid changes and their relevance towards the disease pathogenesis And Lipid Biomarkers and Embryo Quality in In Vitro Fertilization; Pregnancy Success Differentially Expressed by Body Weight | |
| US20150133554A1 (en) | Purification of dpa enriched oil | |
| CN113301892A (zh) | 有益于母亲和/或儿童心理健康的母体dpa | |
| Mari et al. | Metabolic profiles reflect weight loss maintenance and the composition of diet after very-low-energy diet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |